|
| 37861205 | Plasma cell-free DNA methylation analysis for ovarian cancer detection: Analysis of samples from a case-control study and an ovarian cancer screening trial. | Int J Cancer | 2024 |
| 37861205 | Plasma cell-free DNA methylation analysis for ovarian cancer detection: Analysis of samples from a case-control study and an ovarian cancer screening trial. | Int J Cancer | 2024 |
| 36368129 | Profiling the immune landscape in mucinous ovarian carcinoma. | Gynecol Oncol | 2023 |
| 36368129 | Profiling the immune landscape in mucinous ovarian carcinoma. | Gynecol Oncol | 2023 |
| 37843101 | Insights from UKCTOCS for design, conduct and analyses of large randomised controlled trials. | Health Technol Assess | 2023 |
| 37657461 | Tumour stage, treatment, and survival of women with high-grade serous tubo-ovarian cancer in UKCTOCS: an exploratory analysis of a randomised controlled trial. | Lancet Oncol | 2023 |
| 37986811 | NMR metabolomic modelling of age and lifespan: a multi-cohort analysis. | medRxiv | 2023 |
| 37980767 | Ovarian cancer symptoms in pre-clinical invasive epithelial ovarian cancer - An exploratory analysis nested within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). | Gynecol Oncol | 2023 |
| 37147936 | Discovery and validation of serum glycoprotein biomarkers for high grade serous ovarian cancer. | Proteomics Clin Appl | 2023 |
| 36572991 | CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study. | Cancer | 2023 |
| 36948887 | p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study. | J Pathol Clin Res | 2023 |
| 37183782 | Mortality impact, risks, and benefits of general population screening for ovarian cancer: the UKCTOCS randomised controlled trial. | Health Technol Assess | 2023 |
| 36688720 | Lifetime ovulatory years and risk of epithelial ovarian cancer: a multinational pooled analysis. | J Natl Cancer Inst | 2023 |
| 37296935 | Co-Creation of Breast Cancer Risk Communication Tools and an Assessment of Risk Factor Awareness: A Qualitative Study of Patients and the Public in India. | Cancers (Basel) | 2023 |
| 36670203 | Serum biomarker-based early detection of pancreatic ductal adenocarcinomas with ensemble learning. | Commun Med (Lond) | 2023 |
| 37420000 | Thromboxane biosynthesis in cancer patients and its inhibition by aspirin: a sub-study of the Add-Aspirin trial. | Br J Cancer | 2023 |
| 37657461 | Tumour stage, treatment, and survival of women with high-grade serous tubo-ovarian cancer in UKCTOCS: an exploratory analysis of a randomised controlled trial. | Lancet Oncol | 2023 |
| 37843101 | Insights from UKCTOCS for design, conduct and analyses of large randomised controlled trials. | Health Technol Assess | 2023 |
| 37986811 | NMR metabolomic modelling of age and lifespan: a multi-cohort analysis. | medRxiv | 2023 |
| 37980767 | Ovarian cancer symptoms in pre-clinical invasive epithelial ovarian cancer - An exploratory analysis nested within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). | Gynecol Oncol | 2023 |
| 37420000 | Thromboxane biosynthesis in cancer patients and its inhibition by aspirin: a sub-study of the Add-Aspirin trial. | Br J Cancer | 2023 |
| 36948887 | p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study. | J Pathol Clin Res | 2023 |
| 37183782 | Mortality impact, risks, and benefits of general population screening for ovarian cancer: the UKCTOCS randomised controlled trial. | Health Technol Assess | 2023 |
| 37147936 | Discovery and validation of serum glycoprotein biomarkers for high grade serous ovarian cancer. | Proteomics Clin Appl | 2023 |
| 37296935 | Co-Creation of Breast Cancer Risk Communication Tools and an Assessment of Risk Factor Awareness: A Qualitative Study of Patients and the Public in India. | Cancers (Basel) | 2023 |
| 36688720 | Lifetime ovulatory years and risk of epithelial ovarian cancer: a multinational pooled analysis. | J Natl Cancer Inst | 2023 |
| 36572991 | CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study. | Cancer | 2023 |
| 36670203 | Serum biomarker-based early detection of pancreatic ductal adenocarcinomas with ensemble learning. | Commun Med (Lond) | 2023 |
| 34844974 | Comprehensive epithelial tubo-ovarian cancer risk prediction model incorporating genetic and epidemiological risk factors. | J Med Genet | 2022 |
| 34789471 | High Prediagnosis Inflammation-Related Risk Score Associated with Decreased Ovarian Cancer Survival. | Cancer Epidemiol Biomarkers Prev | 2022 |
| 34555263 | Association of hysterectomy and invasive epithelial ovarian and tubal cancer: a cohort study within UKCTOCS. | BJOG | 2022 |
| 34897700 | Validated biomarker assays confirm that ARID1A loss is confounded with MMR deficiency, CD8<sup>+</sup> TIL infiltration, and provides no independent prognostic value in endometriosis-associated ovarian carcinomas. | J Pathol | 2022 |
| 34844974 | Comprehensive epithelial tubo-ovarian cancer risk prediction model incorporating genetic and epidemiological risk factors. | J Med Genet | 2022 |
| 34897700 | Validated biomarker assays confirm that ARID1A loss is confounded with MMR deficiency, CD8<sup>+</sup> TIL infiltration, and provides no independent prognostic value in endometriosis-associated ovarian carcinomas. | J Pathol | 2022 |
| 34555263 | Association of hysterectomy and invasive epithelial ovarian and tubal cancer: a cohort study within UKCTOCS. | BJOG | 2022 |
| 34789471 | High Prediagnosis Inflammation-Related Risk Score Associated with Decreased Ovarian Cancer Survival. | Cancer Epidemiol Biomarkers Prev | 2022 |
| 32766851 | Expanding Our Understanding of Ovarian Cancer Risk: The Role of Incomplete Pregnancies. | J Natl Cancer Inst | 2021 |
| 33670571 | Performance Characteristics of the Ultrasound Strategy during Incidence Screening in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). | Cancers (Basel) | 2021 |
| 33991479 | Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. | Lancet | 2021 |
| 33648562 | UKCTOCS update: applying insights of delayed effects in cancer screening trials to the long-term follow-up mortality analysis. | Trials | 2021 |
| 33494753 | Completeness and accuracy of national cancer and death registration for outcome ascertainment in trials-an ovarian cancer exemplar. | Trials | 2021 |
| 32766851 | Expanding Our Understanding of Ovarian Cancer Risk: The Role of Incomplete Pregnancies. | J Natl Cancer Inst | 2021 |
| 33494753 | Completeness and accuracy of national cancer and death registration for outcome ascertainment in trials-an ovarian cancer exemplar. | Trials | 2021 |
| 33648562 | UKCTOCS update: applying insights of delayed effects in cancer screening trials to the long-term follow-up mortality analysis. | Trials | 2021 |
| 33670571 | Performance Characteristics of the Ultrasound Strategy during Incidence Screening in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). | Cancers (Basel) | 2021 |
| 33991479 | Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. | Lancet | 2021 |
| 31351062 | Serum HE4 and diagnosis of ovarian cancer in postmenopausal women with adnexal masses. | Am J Obstet Gynecol | 2020 |
| 32429029 | Population Study of Ovarian Cancer Risk Prediction for Targeted Screening and Prevention. | Cancers (Basel) | 2020 |
| 32114887 | Circulating Fatty Acids and Risk of Coronary Heart Disease and Stroke: Individual Participant Data Meta-Analysis in Up to 16Â 126 Participants. | J Am Heart Assoc | 2020 |
| 31937926 | Improved early detection of ovarian cancer using longitudinal multimarker models. | Br J Cancer | 2020 |